Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy
- PMID: 23716304
- DOI: 10.1002/mus.23810
Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy
Abstract
This report summarizes the progress made in newborn screening for Duchenne muscular dystrophy (DMD). This subject was discussed fully at a symposium held on September 11-12, 2012, in Bethesda, Maryland, by a group of experts from multiple disciplines. The meeting was triggered by the simultaneous combination of improvements in methods for newborn screening for DMD and greater potential for treatment. On the screening side, a two-tier system of newborn screening was introduced that enabled creatine kinase levels and DMD gene analysis to be done on the same dried blood spots obtained at birth. Treatment improvements included promising results from exon skipping as well as multiple studies showing long-term benefits of glucocorticoids and data indicating that early intervention of both forms of therapy was the most beneficial. Conclusions from this symposium with supportive data could have a significant impact on propelling efforts for approval of newborn screening for DMD.
Copyright © 2013 Wiley Periodicals, Inc.
Similar articles
-
Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.JAMA Neurol. 2016 Jan;73(1):111-6. doi: 10.1001/jamaneurol.2015.3537. JAMA Neurol. 2016. PMID: 26594870 Review.
-
Evidence-based path to newborn screening for Duchenne muscular dystrophy.Ann Neurol. 2012 Mar;71(3):304-13. doi: 10.1002/ana.23528. Ann Neurol. 2012. PMID: 22451200
-
The Early Care (0-3 Years) In Duchenne Muscular Dystrophy Meeting Report.J Neuromuscul Dis. 2024;11(2):525-533. doi: 10.3233/JND-230180. J Neuromuscul Dis. 2024. PMID: 38189762 Free PMC article.
-
Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan.Neurol Sci. 2022 Jul;43(7):4563-4566. doi: 10.1007/s10072-022-06128-2. Epub 2022 May 13. Neurol Sci. 2022. PMID: 35562557 Free PMC article.
-
Duchenne muscular dystrophy: issues in expanding newborn screening.Curr Opin Pediatr. 2007 Dec;19(6):700-4. doi: 10.1097/MOP.0b013e3282f19f65. Curr Opin Pediatr. 2007. PMID: 18025940 Review.
Cited by
-
Evaluation of the Lipid-binding Properties of Recombinant Dystrophin Spectrin-like Repeat Domains R1-3.J Neuromuscul Dis. 2021;8(4):489-494. doi: 10.3233/JND-200622. J Neuromuscul Dis. 2021. PMID: 33780374 Free PMC article.
-
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.JAMA Neurol. 2020 Sep 1;77(9):1122-1131. doi: 10.1001/jamaneurol.2020.1484. JAMA Neurol. 2020. PMID: 32539076 Free PMC article. Clinical Trial.
-
Next-Generation SINE Compound KPT-8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD.Biomedicines. 2022 Sep 26;10(10):2400. doi: 10.3390/biomedicines10102400. Biomedicines. 2022. PMID: 36289662 Free PMC article.
-
Corticosteroid Treatment Impact on Spinal Deformity in Duchenne Muscular Dystrophy.Int Sch Res Notices. 2014 Oct 29;2014:965235. doi: 10.1155/2014/965235. eCollection 2014. Int Sch Res Notices. 2014. PMID: 27382620 Free PMC article. Review.
-
Genomic removal of a therapeutic mini-dystrophin gene from adult mice elicits a Duchenne muscular dystrophy-like phenotype.Hum Mol Genet. 2016 Jul 1;25(13):2633-2644. doi: 10.1093/hmg/ddw123. Epub 2016 Apr 22. Hum Mol Genet. 2016. PMID: 27106099 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical